Expansion of Genedata's Collaboration with Serono into High Content Screening
Genedata announced the expansion of its screening analysis collaboration with Serono. Scientists at Serono now use Genedata's computational solution to combine results from high content screening assays with chemical and pharmacological information as part of the process to identify promising candidates for drug development.
High content data from cellular assay technologies used at Serono enable sophisticated biological profiling. These screening technologies provide insights into the biological effects of potential drug candidates, including possible toxic side effects. To exploit these technologies, screening results need to be shared among people with different expertise, including chemists and toxicologists.
During the course of the collaboration, Genedata extended its Screener® result management and analysis solution, enabling Seronos researchers to analyze and annotate their screening results more efficiently. The collaboration quickly reached the point where the software was a precise fit with Seronos needs, according to the company.
Most read news
Other news from the department business & finance
These products might interest you
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Faster and more efficient thanks to "defects" - Three-dimensional photonic crystals will revolutionize telecommunications
LDL particle measurement by NMR recognized by ADA, ACC - Consensus panel assesses lipoprotein management
Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System
University of Toronto chemists uncover green catalysts